Research and laboratory use only. Not for human consumption.
MOTS-c
MOTS-c is a naturally occurring mitochondrial-derived peptide encoded within a short open reading frame of the mitochondrial 12S ribosomal RNA region. The 16-amino-acid peptide has been studied for its role in metabolic homeostasis, cellular stress adaptation, AMPK signalling, glucose metabolism and communication between mitochondria and the nucleus.
What is MOTS-c?
MOTS-c is a naturally occurring mitochondrial-derived peptide, often abbreviated as an MDP.
Unlike conventional peptide hormones that are encoded in nuclear DNA, MOTS-c is encoded by a short open reading frame located within the mitochondrial 12S ribosomal RNA gene.
The peptide contains 16 amino acids and was first described in 2015 during research investigating whether mitochondrial DNA contains previously unrecognized biologically active micropeptides.
MOTS-c was found to influence cellular metabolism and insulin sensitivity, with skeletal muscle emerging as an important target tissue in early animal research.
Subsequent studies suggested that MOTS-c is involved in cellular responses to metabolic stress and may act as a signal between mitochondria and the nuclear genome.
This has made MOTS-c particularly interesting in research into ageing, metabolic disease, exercise physiology, mitochondrial stress and cellular homeostasis.
What does MOTS-c mean?
MOTS-c is derived from the phrase Mitochondrial Open Reading Frame of the 12S rRNA Type-c .
The name reflects the unusual genetic location from which the peptide is encoded.
This sequence contains sixteen residues: methionine, arginine, tryptophan, glutamine, glutamic acid, methionine, glycine, tyrosine, isoleucine, phenylalanine, tyrosine, proline, arginine, lysine, leucine and arginine.
MOTS-c is therefore fundamentally different from synthetic analogues such as GHRP-6, Hexarelin or Ipamorelin. Its amino-acid sequence originates from the human mitochondrial genome.
Researchers identified a previously unrecognized short open reading frame within mitochondrial 12S rRNA that encoded a biologically active 16-amino-acid peptide.
How was MOTS-c discovered?
For many years, mitochondrial DNA was thought to encode only a relatively small set of conventional proteins required for oxidative phosphorylation, together with ribosomal and transfer RNAs.
Discovery of the mitochondrial peptide humanin suggested that small open reading frames hidden within mitochondrial RNA genes might encode additional functional peptides.
In 2015, researchers reported a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA region and named it MOTS-c.
The original study showed that MOTS-c influenced metabolic homeostasis, improved insulin sensitivity in mouse models and interacted with pathways involving the folate cycle, purine biosynthesis and AMPK.
That discovery expanded the concept of mitochondria from energy-producing organelles to active signalling centres capable of encoding regulatory peptides .
Amino-acid structure
MOTS-c is a short 16-residue peptide encoded by mitochondrial DNA rather than the nuclear genome.
Why is mitochondrial encoding important?
Most peptide hormones and signalling proteins are encoded by nuclear DNA, translated in the cytoplasm and then processed through conventional cellular pathways.
MOTS-c challenges that traditional model because its coding sequence is embedded within a mitochondrial ribosomal RNA region.
Mitochondria contain their own genome, inherited almost entirely through the maternal line, and have traditionally been viewed mainly in terms of cellular energy production.
Mitochondrial-derived peptides such as MOTS-c and humanin provide evidence that the mitochondrial genome also contributes directly to cell signalling.
This has led to the broader concept of mitonuclear communication: mitochondria can transmit information about cellular energy state and stress to the nucleus, allowing coordinated changes in gene expression.
Why are researchers interested in MOTS-c?
MOTS-c sits at the intersection of mitochondrial function, energy sensing, insulin action, exercise biology and cellular adaptation to metabolic stress.
Energy Metabolism
MOTS-c has been linked to cellular energy sensing and AMPK-related metabolic adaptation.
Glucose Regulation
Early animal studies found improved insulin sensitivity and glucose metabolism, particularly in skeletal muscle.
Exercise Biology
MOTS-c expression and circulating levels have been studied in relation to exercise and mitochondrial stress adaptation.
Ageing Research
Circulating MOTS-c levels and cellular responses have been investigated in ageing and age-related metabolic decline.
How does MOTS-c influence cellular metabolism?
MOTS-c appears to act through multiple pathways rather than through a single classical cell- surface peptide receptor.
AMPK Activation
MOTS-c research consistently implicates AMP-activated protein kinase, a major cellular energy-sensing pathway.
Folate Cycle
Early work showed inhibition of the folate cycle and linked de novo purine biosynthesis.
AICAR Accumulation
Changes in purine metabolism can increase AICAR, an endogenous metabolite capable of activating AMPK.
Nuclear Gene Regulation
During metabolic stress, MOTS-c can translocate to the nucleus and alter adaptive stress-response gene expression.
MOTS-c can act inside the nucleus
One of the most unusual aspects of MOTS-c biology is its ability to participate directly in communication between mitochondria and the nuclear genome.
Under metabolic stress conditions, research has demonstrated stress-dependent nuclear translocation of MOTS-c.
Once in the nucleus, MOTS-c has been associated with regulation of genes containing antioxidant response elements and genes involved in cellular adaptation to stress.
This provides a potential mechanism by which mitochondrial genetic information can influence nuclear transcription in response to changing cellular conditions.
The finding is significant because it challenges the traditional view that genetic signalling primarily flows from the nucleus toward mitochondria.
What potential applications are being investigated?
The areas below represent scientific hypotheses arising from preclinical and observational research. They are not established therapeutic indications for native MOTS-c.
Insulin Resistance & Type 2 Diabetes
Animal studies demonstrating improved insulin sensitivity and glucose handling created interest in MOTS-c as a potential metabolic signalling target.
Energy Balance & Adiposity
Early mouse research found protection against diet-induced obesity and metabolic dysfunction, although human therapeutic efficacy is not established.
Exercise Adaptation
MOTS-c is associated with skeletal-muscle metabolic responses and has been studied in relation to exercise-induced mitochondrial stress and physical performance.
Age-Related Metabolic Decline
Observational and experimental studies have linked MOTS-c to age-related changes in mitochondrial function, metabolism and cellular stress resilience.
Vascular & Cardiac Biology
Preclinical studies have investigated possible protective effects in vascular dysfunction, cardiac stress and inflammation.
Neurodegenerative Research
Mitochondrial dysfunction is central to several neurodegenerative disorders, generating interest in mitochondrial- derived peptides as stress-response regulators.
Findings in cells and animals do not establish that MOTS-c treats diabetes, obesity, ageing, cardiovascular disease, neurological disease or any other human condition.
How strong is the evidence?
MOTS-c has a substantial and growing mechanistic literature, but direct therapeutic evidence in humans remains limited.
Molecular Evidence
Mitochondrial encoding, AMPK involvement and stress-related nuclear translocation are well documented experimentally.
Animal Evidence
Multiple animal studies demonstrate metabolic, exercise-related and stress-response effects.
Human Observational Evidence
Circulating levels and genetic variation have been associated with ageing, metabolism and physical function in human studies.
Therapeutic Human Evidence
Clinical efficacy of native MOTS-c as a medicine has not been established.
What do we know in humans?
Human observational biology exists, but native MOTS-c has not been validated as an approved therapeutic medicine.
MOTS-c is naturally detectable in human tissues and circulation, supporting the concept that it has physiological rather than purely experimental relevance.
Human observational research has examined circulating MOTS-c concentrations in relation to age, metabolic state, exercise and disease.
Reviews report that circulating levels may decline with age, while exercise and metabolic stress can alter expression in tissue-specific ways.
Genetic research has also focused on mitochondrial variants affecting the MOTS-c coding sequence and their possible relationships with longevity and metabolic phenotype.
These findings do not establish that administering synthetic MOTS-c improves lifespan, diabetes, muscle function, exercise performance or other human outcomes.
The strongest clinical-development work to date relates instead to CB4211, an investigational MOTS-c analogue rather than native MOTS-c itself.
MOTS-c and CB4211 are not the same compound
Clinical-development data for CB4211 should not be presented as if it were a direct clinical trial of native MOTS-c.
CB4211
CB4211 is an investigational analogue derived from MOTS-c biology and developed for metabolic disease research.
CB4211 progressed into a three-part Phase 1a/1b programme designed to examine safety, tolerability, pharmacokinetics and pharmacodynamics.
The first parts studied single and multiple ascending doses in healthy, non-obese adults.
A later part studied repeated exposure over 28 days in people with nonalcoholic fatty liver disease .
ClinicalTrials.gov records 88 enrolled participants and study completion in April 2021.
CB4211 should be regarded as a MOTS-c-derived investigational analogue , not simply another name for the native mitochondrial peptide.
Therefore any safety or pharmacodynamic findings from CB4211 cannot automatically define the safety or therapeutic efficacy of native synthetic MOTS-c.
Where is MOTS-c in clinical development?
Native MOTS-c remains principally a biological and preclinical research peptide. A related analogue has progressed into early human trials.
Native mitochondrial peptide with early translational development
MOTS-c has a strong mechanistic and preclinical research base, while direct therapeutic clinical development has focused primarily on a related analogue.
What don't we know?
Factors affecting MOTS-c stability
MOTS-c is a short synthetic peptide when prepared as a research reagent. Stability depends on the exact chemical form, purity, formulation, temperature and solution conditions documented for the research material.
Temperature
Elevated temperature can accelerate chemical degradation and loss of peptide integrity.
Moisture
Humidity and repeated environmental exposure can alter lyophilized peptide stability.
Solution Conditions
pH, solvent, buffer and concentration may influence stability after material is placed in solution.
Material Specification
Purity, counter-ion and analytical identity should be established for the specific laboratory material under study.
Endogenous mitochondrial peptide — therapeutic use remains investigational
MOTS-c is a naturally occurring mitochondrial-derived peptide with a substantial mechanistic and preclinical research literature.
Human studies support physiological relevance through circulating levels, exercise responses and associations with metabolic and age-related phenotypes.
However, native MOTS-c has not been established as an approved treatment for obesity, insulin resistance, diabetes, ageing, exercise performance, cardiovascular disease or any other human condition.
A related analogue, CB4211, completed Phase 1a/1b investigation, but that clinical programme should not be treated as direct therapeutic evidence for native MOTS-c.
ASA Research Labs provides this information for scientific and educational purposes only. Nothing on this page should be interpreted as medical advice, dosing guidance or a recommendation for human use.
Selected scientific references
Selected literature covering the discovery, mitochondrial origin, metabolic signalling, nuclear translocation, exercise biology, ageing research and clinical development of related MOTS-c analogues.
Scientific research information only
This profile is provided for scientific and educational information. MOTS-c is a naturally occurring mitochondrial-derived peptide, but synthetic MOTS-c is not presented by ASA Research Labs as an approved treatment for insulin resistance, diabetes, obesity, ageing, exercise performance, cardiovascular disease, neurological disease or any other human condition. Laboratory, animal, observational and analogue clinical data do not establish therapeutic safety or efficacy of native MOTS-c in humans. This page does not provide instructions for administration, dosing or human use.